Back to News
Market Impact: 0.2
Korro Bio Doses First Cohort In Phase 1/2 Study Of KRRO-121 For Hyperammonemia
Source: Nasdaq
Healthcare & Biotech
Korro Bio reported that the first cohort has been dosed in the Phase 1/2 study of KRRO-121. The investigational therapy is being studied for hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy; the article provides no efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
KRRO0.50
More News
- Profound Medical stock surges 20% on raised Q3 revenue outlook
- Medical device maker Centinel Spine discloses revenue rise in US IPO filing
- Halozyme stock rises after winning injunction against Merck
- BTIG cuts ArriVent BioPharma stock price target on trial results
- MustGrow Biologics at 20th iif: sales grow as Bayer backs pipeline
- Healthcare Services Group acquires NEXDINE Hospitality for $93.5M